Edgewise Therapeutics
EWTX
About: Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
Employees: 126
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
126% more repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 39
2.28% more ownership
Funds ownership: 110.59% [Q1] → 112.87% (+2.28%) [Q2]
7% less funds holding
Funds holding: 191 [Q1] → 178 (-13) [Q2]
20% less funds holding in top 10
Funds holding in top 10: 10 [Q1] → 8 (-2) [Q2]
24% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 41
33% less call options, than puts
Call options by funds: $775K | Put options by funds: $1.15M
33% less capital invested
Capital invested by funds: $2.32B [Q1] → $1.56B (-$763M) [Q2]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
|
JP Morgan
Tessa Romero
|
$30
|
Overweight
Maintained
|
19 Aug 2025 |
|
RBC Capital
Leonid Timashev
|
$49
|
Outperform
Maintained
|
8 Aug 2025 |
|
HC Wainwright & Co.
Joseph Pantginis
|
$42
|
Buy
Initiated
|
30 Jun 2025 |
Financial journalist opinion
Based on 4 articles about EWTX published over the past 30 days
